Neximmune, INC

NexImmune's board and executive team resign en masse as the company moves forward with its plan of liquidation and dissolution.

NexImmune stockholders voted to approve the company's dissolution and liquidation plan at a special meeting held on August 9, 2024.

NexImmune has adjourned its special meeting to vote on liquidation, seeking alternatives to maximize value, and will reconvene on August 9, 2024.

NexImmune has adjourned its special meeting of stockholders to explore alternatives to liquidation, with the meeting scheduled to reconvene on August 2, 2024.

NexImmune, Inc. has received a delisting notice from Nasdaq and has adjourned a special meeting to consider liquidation, while it explores alternatives to maximize value.

NexImmune, Inc. has amended its bylaws to change quorum requirements and created a Series A Preferred Stock with special voting rights related to potential liquidation.

NexImmune reports a net loss of $2.3 million for Q2 2024 as it focuses on its AIM INJ platform and explores strategic alternatives amid substantial doubt about its ability to continue as a going concern.

NexImmune's Q1 2024 report reveals reduced operating expenses but raises concerns about its ability to continue as a going concern due to recurring losses and limited cash reserves.

NexImmune's 2023 10-K filing reveals a strategic realignment towards its AIM INJ platform, pausing clinical trials due to resource constraints, and ongoing efforts to secure additional funding.